Boston Scientific Corporation provided earnings guidance for the First Quarter and full year of 2024. For the quarter, the company estimates net sales growth versus the prior year period, to be in a range of approximately 7.5% to 9.5% on a reported basis, and approximately 7% to 9% on an organic basis. First quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.29 to $0.31.

For the year, the company estimates net sales growth versus the prior year period, to be in a range of approximately 8.5% to 9.5% on a reported basis, and approximately 8% to 9% on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.38 to $1.42.